Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 3
2005 3
2007 3
2008 1
2009 3
2010 5
2011 3
2012 8
2013 10
2014 4
2015 5
2016 6
2017 5
2018 8
2019 7
2020 19
2021 18
2022 16
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

126 results

Results by year

Filters applied: . Clear all
Page 1
Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency.
Aminov S, Giricz O, Melnekoff DT, Sica RA, Polishchuk V, Papazoglu C, Yates B, Wang HW, Sahu S, Wang Y, Gordon-Mitchell S, Leshchenko VV, Schinke C, Pradhan K, Aluri S, Sohn M, Barta SK, Agarwal B, Goldfinger M, Mantzaris I, Shastri A, Matsui W, Steidl U, Brody JD, Shah NN, Parekh S, Verma A. Aminov S, et al. Among authors: parekh s. J Clin Invest. 2024 Feb 20;134(8):e175199. doi: 10.1172/JCI175199. J Clin Invest. 2024. PMID: 38376944 Free PMC article.
Regression of smoldering myeloma with treatment of Gaucher disease.
Barley K, Parekh A, Salam S, Mendu DR, Shukla RP, Vatti D, Verina D, Stauffer C, Salib C, El Jamal S, Teruya-Feldstein J, Duffield AS, Leshchenko VV, Jagannath S, Balwani M, Parekh S. Barley K, et al. Among authors: parekh s. Blood Adv. 2024 Apr 9;8(7):1634-1638. doi: 10.1182/bloodadvances.2023012304. Blood Adv. 2024. PMID: 38285963 Free PMC article. No abstract available.
Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies.
Stevens MM, Kimmerling RJ, Olcum S, Vacha M, LaBella R, Minnah A, Katsis K, Fujii J, Shaheen Z, Sundaresan S, Criscitiello J, Niesvizky R, Raje N, Branagan A, Krishnan A, Jagannath S, Parekh S, Sperling AS, Rosenbaum CA, Munshi N, Luskin MR, Tamrazi A, Reid CA. Stevens MM, et al. Among authors: parekh s. JCO Precis Oncol. 2024 Jan;8:e2300349. doi: 10.1200/PO.23.00349. JCO Precis Oncol. 2024. PMID: 38237098 Free PMC article.
Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.
Aleman A, van Kesteren M, Zajdman AK, Srivastava K, Cognigni C, Mischka J, Chen LY, Upadhyaya B, Serebryakova K, Nardulli JR, Lyttle N, Kappes K, Jackson H, Gleason CR, Oostenink A, Cai GY, Van Oekelen O; PVI/MM/Seronet Study Group; van Bakel H, Sordillo EM, Cordon-Cardo C, Merad M, Jagannath S, Wajnberg A, Simon V, Parekh S. Aleman A, et al. Among authors: parekh s. EBioMedicine. 2023 Dec;98:104886. doi: 10.1016/j.ebiom.2023.104886. Epub 2023 Nov 22. EBioMedicine. 2023. PMID: 37995467 Free PMC article.
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.
Shah UA, Moshier E, Derkach A, Huang Y, Mailankody S, Tan CR, Maclachlan K, Hultcrantz M, Korde N, Hassoun H, Thibaud S, Sanchez L, Rodriguez C, Richard S, Richter J, Rossi A, Cho HJ, Lesokhin A, Chari A, Usmani SZ, Jagannath S, Parekh S, Gallagher EJ. Shah UA, et al. Among authors: parekh s. Blood Adv. 2024 Jan 9;8(1):236-247. doi: 10.1182/bloodadvances.2023010815. Blood Adv. 2024. PMID: 37772981 Free PMC article.
IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.
Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, Cho HJ, Parekh SS, Richard S, Richter J, Rodriguez C, Rossi A, Sanchez LJ, Thibaud S, Jagannath S, Chari A. Lancman G, et al. Among authors: parekh ss. Blood Cancer Discov. 2023 Nov 1;4(6):440-451. doi: 10.1158/2643-3230.BCD-23-0049. Blood Cancer Discov. 2023. PMID: 37769148
PRMT5 supports multiple oncogenic pathways in mantle cell lymphoma.
Sloan SL, Brown F, Long M, Weigel C, Koirala S, Chung JH, Pray B, Villagomez L, Hinterschied C, Sircar A, Helmig-Mason J, Prouty A, Brooks E, Youssef Y, Hanel W, Parekh S, Chan WK, Chen Z, Lapalombella R, Sehgal L, Vaddi K, Scherle P, Chen-Kiang S, Di Liberto M, Elemento O, Meydan C, Foox J, Butler D, Mason CE, Baiocchi RA, Alinari L. Sloan SL, et al. Among authors: parekh s. Blood. 2023 Sep 7;142(10):887-902. doi: 10.1182/blood.2022019419. Blood. 2023. PMID: 37267517
Correction: Triple MAPK inhibition salvaged a relapsed post-BCMA CAR-T cell therapy multiple myeloma patient with a BRAF V600E subclonal mutation.
Elnaggar M, Agte S, Restrepo P, Ram M, Melnekoff D, Adamopoulos C, Stevens MM, Kappes K, Leshchenko V, Verina D, Jagannath S, Poulikakos PI, Parekh S, Laganà A. Elnaggar M, et al. Among authors: parekh s. J Hematol Oncol. 2023 May 8;16(1):52. doi: 10.1186/s13045-023-01449-x. J Hematol Oncol. 2023. PMID: 37158935 Free PMC article. No abstract available.
126 results